Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Antibody-conjugated, dual-modal, near-infrared fluorescent iron oxide nanoparticles for antiamyloidgenic activity and specific detection of amyloid-β fibrils.

Skaat H, Corem-Slakmon E, Grinberg I, Last D, Goez D, Mardor Y, Margel S.

Int J Nanomedicine. 2013;8:4063-76. doi: 10.2147/IJN.S52833. Epub 2013 Oct 29.

2.

Dimeric bis (heptyl)-Cognitin Blocks Alzheimer's β-Amyloid Neurotoxicity Via the Inhibition of Aβ Fibrils Formation and Disaggregation of Preformed Fibrils.

Hu SQ, Wang R, Cui W, Mak SH, Li G, Hu YJ, Lee MY, Pang YP, Han YF.

CNS Neurosci Ther. 2015 Dec;21(12):953-61. doi: 10.1111/cns.12472. Epub 2015 Oct 28.

PMID:
26507365
3.

Alzheimer's disease amyloid β-protein mutations and deletions that define neuronal binding/internalization as early stage nonfibrillar/fibrillar aggregates and late stage fibrils.

Poduslo JF, Howell KG, Olson NC, Ramirez-Alvarado M, Kandimalla KK.

Biochemistry. 2012 May 15;51(19):3993-4003. doi: 10.1021/bi300275g. Epub 2012 May 7.

PMID:
22545812
4.

Protease inhibitor coinfusion with amyloid beta-protein results in enhanced deposition and toxicity in rat brain.

Frautschy SA, Horn DL, Sigel JJ, Harris-White ME, Mendoza JJ, Yang F, Saido TC, Cole GM.

J Neurosci. 1998 Oct 15;18(20):8311-21.

5.

Surface plasmon resonance binding kinetics of Alzheimer's disease amyloid beta peptide-capturing and plaque-binding monoclonal antibodies.

Ramakrishnan M, Kandimalla KK, Wengenack TM, Howell KG, Poduslo JF.

Biochemistry. 2009 Nov 3;48(43):10405-15. doi: 10.1021/bi900523q.

6.

Amyloid binding ligands as Alzheimer's disease therapies.

Lee VM.

Neurobiol Aging. 2002 Nov-Dec;23(6):1039-42. Review.

PMID:
12470800
7.

Engineered polymer nanoparticles containing hydrophobic dipeptide for inhibition of amyloid-β fibrillation.

Skaat H, Chen R, Grinberg I, Margel S.

Biomacromolecules. 2012 Sep 10;13(9):2662-70. doi: 10.1021/bm3011177. Epub 2012 Aug 28.

PMID:
22897679
8.

Anti-ApoE antibody given after plaque onset decreases Aβ accumulation and improves brain function in a mouse model of Aβ amyloidosis.

Liao F, Hori Y, Hudry E, Bauer AQ, Jiang H, Mahan TE, Lefton KB, Zhang TJ, Dearborn JT, Kim J, Culver JP, Betensky R, Wozniak DF, Hyman BT, Holtzman DM.

J Neurosci. 2014 May 21;34(21):7281-92. doi: 10.1523/JNEUROSCI.0646-14.2014.

9.

Synthesis of fluorescent-maghemite nanoparticles as multimodal imaging agents for amyloid-beta fibrils detection and removal by a magnetic field.

Skaat H, Margel S.

Biochem Biophys Res Commun. 2009 Sep 4;386(4):645-9. doi: 10.1016/j.bbrc.2009.06.110. Epub 2009 Jun 24.

PMID:
19559008
10.

Design of near-infrared fluorescent bioactive conjugated functional iron oxide nanoparticles for optical detection of colon cancer.

Corem-Salkmon E, Perlstein B, Margel S.

Int J Nanomedicine. 2012;7:5517-27. doi: 10.2147/IJN.S33710. Epub 2012 Oct 19.

11.

Smart near-infrared fluorescence probes with donor-acceptor structure for in vivo detection of β-amyloid deposits.

Cui M, Ono M, Watanabe H, Kimura H, Liu B, Saji H.

J Am Chem Soc. 2014 Mar 5;136(9):3388-94. doi: 10.1021/ja4052922. Epub 2014 Feb 20.

PMID:
24555862
12.

BRCAA1 monoclonal antibody conjugated fluorescent magnetic nanoparticles for in vivo targeted magnetofluorescent imaging of gastric cancer.

Wang K, Ruan J, Qian Q, Song H, Bao C, Zhang X, Kong Y, Zhang C, Hu G, Ni J, Cui D.

J Nanobiotechnology. 2011 May 25;9:23. doi: 10.1186/1477-3155-9-23.

13.

S14G-humanin inhibits Aβ1-42 fibril formation, disaggregates preformed fibrils, and protects against Aβ-induced cytotoxicity in vitro.

Zhang W, Du Y, Bai M, Xi Y, Li Z, Miao J.

J Pept Sci. 2013 Mar;19(3):159-65. doi: 10.1002/psc.2484. Epub 2013 Jan 24. Erratum in: J Pept Sci. 2016 Jun;22(6):434.

PMID:
23349038
14.

Curcumin-conjugated magnetic nanoparticles for detecting amyloid plaques in Alzheimer's disease mice using magnetic resonance imaging (MRI).

Cheng KK, Chan PS, Fan S, Kwan SM, Yeung KL, Wáng YX, Chow AH, Wu EX, Baum L.

Biomaterials. 2015 Mar;44:155-72. doi: 10.1016/j.biomaterials.2014.12.005. Epub 2015 Jan 12.

PMID:
25617135
15.

Attenuation of lysozyme amyloid cytotoxicity by SPION-mediated modulation of amyloid aggregation.

Naik A, Kambli P, Borana M, Mohanpuria N, Ahmad B, Kelkar-Mane V, Ladiwala U.

Int J Biol Macromol. 2015 Mar;74:439-46. doi: 10.1016/j.ijbiomac.2014.12.040. Epub 2015 Jan 3.

PMID:
25562831
16.

Mostly separate distributions of CLAC- versus Abeta40- or thioflavin S-reactivities in senile plaques reveal two distinct subpopulations of beta-amyloid deposits.

Kowa H, Sakakura T, Matsuura Y, Wakabayashi T, Mann DM, Duff K, Tsuji S, Hashimoto T, Iwatsubo T.

Am J Pathol. 2004 Jul;165(1):273-81.

17.

How do membranes initiate Alzheimer's Disease? Formation of toxic amyloid fibrils by the amyloid β-protein on ganglioside clusters.

Matsuzaki K.

Acc Chem Res. 2014 Aug 19;47(8):2397-404. doi: 10.1021/ar500127z. Epub 2014 Jul 16.

PMID:
25029558
18.

Stabilization of native amyloid β-protein oligomers by Copper and Hydrogen peroxide Induced Cross-linking of Unmodified Proteins (CHICUP).

Williams TL, Serpell LC, Urbanc B.

Biochim Biophys Acta. 2016 Mar;1864(3):249-59. doi: 10.1016/j.bbapap.2015.12.001. Epub 2015 Dec 15.

PMID:
26699836
19.

Selection of aptamers for amyloid beta-protein, the causative agent of Alzheimer's disease.

Rahimi F, Bitan G.

J Vis Exp. 2010 May 13;(39). pii: 1955. doi: 10.3791/1955.

20.

Supplemental Content

Support Center